Company intelligence / Profile preview

NanoNewron

Not explicitly stated; likely Europe based on language and style but not confirmed.nanonewron.com ↗

Ownership: Private
Development stage: Other

Overview

NanoNewron is developing a patented platform technology, NewroBus™, which uses single-chain nanobodies targeting transferrin receptor 1 to shuttle biologics across the blood-brain barrier. Their lead candidate, NN-841—a heterotrimer of their proprietary nanobody and two TNF-alpha inhibitors—has demonstrated high brain penetration and potent TNF-alpha inhibition in animal models with excellent tolerability. No human clinical data reported yet.

Therapeutic areas: Neurology
Modalities: Nanobody therapyBiologicAntibody (specifically single-chain nanobodies)Fusion protein (heterotrimeric constructs)
Industry: Biotech

Drug pipeline

8 assets

NN-841

Preclinical

7 more assets in the full pipeline.

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on NanoNewron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoNewron.